Featured Research

from universities, journals, and other organizations

New Findings Explain T-Cell Loss In HIV Infection

Date:
December 12, 2001
Source:
NIH/National Institute Of Allergy And Infectious Diseases
Summary:
For a number of years, many scientists have believed that HIV depletes its primary target, CD4+ T cells, by blocking new T-cell production. Two independent studies now challenge that point of view, showing that HIV does not block such production but instead accelerates the division of existing T cells.

For a number of years, many scientists have believed that HIV depletes its primary target, CD4+ T cells, by blocking new T-cell production. Two independent studies now challenge that point of view, showing that HIV does not block such production but instead accelerates the division of existing T cells.

Following the initiation of highly active antiretroviral therapy, or HAART, there is an immediate drop in the rate of T-cell production accompanied by an even greater decrease in the rate of CD4 T-cell death. Thus, the increases in CD4+ T-cell counts seen following HAART are not due to a boost in the production of new T cells. Rather, they are caused by a slowdown in the loss of existing T cells.

"These two studies have come to the same conclusion, namely that the primary cause of the immunodeficiency associated with HIV infection is an increase in the rate of CD4+ T-cell death," notes Anthony S. Fauci, M.D., Director of the National Institute of Allergy and Infectious Diseases, which funded both studies. "This research sheds light on how we might best reduce the decline in those cells in the setting of HIV infection and more effectively treat people with HIV."

David Ho, M.D., a coauthor of one of the studies, adds, "These two papers should put to rest a controversy that has been part of the scientific debate in HIV research for the past decade."

Using different sophisticated methods to directly study the growth and death of individual T cells in people infected with HIV, researchers from NIH and the Aaron Diamond AIDS Research Center at The Rockefeller University independently studied the virus' effects on T-cell dynamics in treated and untreated individuals.

In the NIH study, reported today in the Journal of Experimental Medicine online and scheduled for print in the December 17 issue, Joseph Kovacs, M.D., and his colleagues attached chemical tags to dividing cells to monitor the fates of individual T cells in 17 HIV-infected patients before and after the initiation of HAART.

Their results showed that high HIV levels did not block T-cell production, but instead caused those cells to multiply and divide more rapidly. When patients were treated with antiretroviral drugs, T-cell proliferation and death both slowed.

Their findings are in agreement with those published recently in the same journal by Dr. Ho, Hiroshi Mohri, M.D., and their colleagues at the Aaron Diamond AIDS Research Center.

At the same time as the NIAID team was conducting its study, Drs. Ho and Mohri were using a different technique to monitor and compare T-cell proliferation in seven people with HIV infection before and after HAART therapy and in four uninfected individuals.

Their studies found the same effect of HIV infection on T-cell production. They were also able to demonstrate that HIV infection increased T-cell proliferation, again indicating that the loss of CD4+ T cells in the setting of HIV infection is due to an increase in destruction, not a decrease in production.

NIAID is a component of the National Institutes of Health (NIH). NIAID supports basic and applied research to prevent, diagnose, and treat infectious and immune-mediated illnesses, including HIV/AIDS and other sexually transmitted diseases, tuberculosis, malaria, autoimmune disorders, asthma and allergies.

References:

JA Kovacs et al. Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. Journal of Experimental Medicine 194:1731-41 (2001).

H Mohri et al. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. Journal of Experimental Medicine 194:1277-87 (2001).

Press releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov


Story Source:

The above story is based on materials provided by NIH/National Institute Of Allergy And Infectious Diseases. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Institute Of Allergy And Infectious Diseases. "New Findings Explain T-Cell Loss In HIV Infection." ScienceDaily. ScienceDaily, 12 December 2001. <www.sciencedaily.com/releases/2001/12/011210163733.htm>.
NIH/National Institute Of Allergy And Infectious Diseases. (2001, December 12). New Findings Explain T-Cell Loss In HIV Infection. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2001/12/011210163733.htm
NIH/National Institute Of Allergy And Infectious Diseases. "New Findings Explain T-Cell Loss In HIV Infection." ScienceDaily. www.sciencedaily.com/releases/2001/12/011210163733.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins